Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of eftrenonacog alfa in previously treated patients with hemophilia B
2011-003075-11Phase 3Completed
- Sponsor
- Biogen
- Start
- Sep 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eftrenonacog alfa in hemophilia B (HB), sponsored by Biogen. Primary endpoint: Occurrence of inhibitor development. Started Sep 2011; status: completed.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-003075-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003075-11.